Med­Co builds its case for star cho­les­terol RNAi ther­a­py with two new pos­i­tive piv­otal stud­ies

6 years ago
R&D

Cana­di­an star re­searcher Bren­dan Frey bran­dish­es Deep Ge­nomic­s' first AI-dis­cov­ered drug

6 years ago
AI
Discovery

Top GSK/Vi­iV sci­en­tist who co-in­vent­ed an HIV block­buster books a trip to biotech

6 years ago
People
R&D

'Worse than ever,' Boston's biotechs stare down traf­fic cri­sis — prompt­ing call for more re­mote work­ing, flex hours

6 years ago
Pharma

Boehringer In­gel­heim backs Max Planck spin­out in tak­ing a shot at tough class of can­cer tar­gets

6 years ago
Financing
Startups

FDA en­dors­es Bavar­i­an Nordic's mon­key­pox vac­cine, mark­ing world's first ap­proval

6 years ago
R&D
FDA+

Reg­u­la­tors throw up an­oth­er hur­dle to Roche’s $4.3B Spark ac­qui­si­tion as ques­tions per­co­late over he­mo­phil­ia mar­ket ...

6 years ago
Deals
Cell/Gene Tx

Com­ing out of Chap­ter 11, Aege­ri­on jumps in­to wel­come arms of Irish phar­ma with big plans, fresh $60M for its drugs

6 years ago
Deals

No­var­tis ac­cus­es 2 AveX­is founders of al­ter­ing da­ta, stonewalling probe — but ex-CSO blasts back

6 years ago
Pharma
Cell/Gene Tx

Eli Lil­ly dish­es out first mile­stone pay­ment for Alzheimer's deal; ADC Ther­a­peu­tics, Viela Bio set terms for IPO

6 years ago
News Briefing

Hy­po­glycemia 'Epipen' clears Phase III, hur­tles to­ward FDA de­ci­sion

6 years ago
R&D

Cerev­el plots first late-stage move as Pfiz­er drug comes through in PhII Parkin­son's tri­al

6 years ago
R&D

Uro­Gen steers to­wards its first com­mer­cial drug launch, armed with strong da­ta on lead ther­a­py

6 years ago
R&D

Bay Area biotech hauls in $62M to pay the freight on ear­ly-stage CD33/CD3 T cell en­gager

6 years ago
R&D

Em­bat­tled AM­AG braces for Oc­to­ber FDA Mak­e­na ad­com, but it need not wor­ry — an­a­lyst

6 years ago
R&D
FDA+

Is Re­gen­eron los­ing its R&D mys­tique? An­a­lyst dis­counts big biotech’s run­ner-up de­vel­op­ment strat­e­gy in an ...

6 years ago
R&D

Start­up EPM launch­es, high off cannabi­noid acid in­no­va­tion

6 years ago
Startups

Ex-Retrophin BD chief flips his rare dis­ease start­up on­to Nas­daq via re­verse merg­er with Pro­teon

6 years ago
Deals

Lund­beck’s Deb­o­rah Dun­sire didn’t just want an ex-US deal for Alder’s mi­graine drug. She want­ed the whole world

6 years ago
Deals

GW Phar­ma's cannabis-de­rived epilep­sy med­i­cine makes the cut in the Eu­ro­pean Union

6 years ago
FDA+

Servi­er be­gins manslaugh­ter tri­al over weight loss drug

6 years ago
Pharma

Once tout­ed as Lyri­ca ri­val for di­a­bet­ic nerve pain, Ko­re­an biotech's plas­mid prod­uct im­plodes in PhI­II

6 years ago
R&D

As­traZeneca vet heads to UK biotech as the new CSO; Mallinck­rodt touts pos­i­tive PhI­II da­ta

6 years ago
News Briefing

FDA puts the brakes on a rare dis­ease biotech’s PhI­II as reg­u­la­tors wait for an up­date — shares crum­ble

6 years ago
R&D
FDA+
First page Previous page 896897898899900901902 Next page Last page
A service from the Financial Times